Currentculinary health fundPolicy N/A

Rituxan Hycela (rituximab + hyaluronidase) — Coverage Criteria

Defines prior authorization, medical necessity criteria, dosing, and indications for Rituxan Hycela (subcutaneous rituximab + hyaluronidase) for adult oncology indications and select other hematologic/inflammatory syndromes for members of Culinary Health Fund.

Policy Summary

Payerculinary health fund

PolicyRituxan Hycela (rituximab + hyaluronidase) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 18, 2026

Key ActionObtain prior authorization and document at least one full IV rituximab dose before initiating Rituxan Hycela.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18minimum patient age for approvals

1 yearstandard authorization duration for approvals

1,400 mgcommon SC dose

1,600 mgalternate SC dose

must receive IVIV induction required

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Rituxan Hycela

Initial authorization criteria and dosing

Covered when ALL of the following are met for each indication (criteria and dosing given per indication).

General requirements for FDA-approved and supportive indications: A) Patient is ≥ 18 years of age; AND B) Patient has already received at least one full dose of rituximab intravenous; AND C) Rituxan Hycela is administered under the care of a healthcare professional; AND D) The medication is being prescribed by or in consultation with an oncologist.

Applies across listed indications unless an indication adds extra criteria.

Indications covered (each with dosing and authorization duration of 1 year): Approved indications include: 1) B‑cell lymphomas (examples listed); 2) Chronic lymphocytic leukemia / small lymphocytic lymphoma; 3) Castleman disease; 4) Hairy cell leukemia; 5) Nodular lymphocyte‑predominant Hodgkin lymphoma; 6) Kaposi sarcoma with KSHV‑associated inflammatory cytokine syndrome (KICS); 7) Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.

Specific dosing per indication provided in policy (see dosing nodes).

Dosing options by indication: Dosing options include fixed subcutaneous regimens: 1,400 mg rituximab + 23,400 units hyaluronidase; or 1,600 mg rituximab + 26,800 units hyaluronidase. Dosing schedules vary by indication (e.g., 1,400 mg with doses separated by ≥7 days for many conditions; CLL/SLL dosing 1,600 mg on Day 1 of each cycle). For Waldenstrom's, a maximum of four doses per 28‑day cycle is specified.

Approvals limited to these dosing regimens and usual authorization duration of 1 year.

B‑Cell Lymphoma specific dosing: Approve for 1 year if ALL general requirements are met. Dosing: 1,400 mg rituximab + 23,400 units hyaluronidase subcutaneously, with doses separated by at least 7 days.

Examples of B‑cell lymphomas are listed in policy (DLBCL, follicular, MALT, mantle cell, etc.).

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma specific dosing: Approve for 1 year if ALL general requirements are met. Dosing: 1,600 mg rituximab + 26,800 units hyaluronidase given subcutaneously on Day 1 of each cycle.

Applies to previously treated and previously untreated disease per policy.

Castleman disease and Hairy cell leukemia dosing: Approve for 1 year if ALL general requirements are met. Dosing options: either 1,400 mg rituximab + 23,400 units hyaluronidase subcutaneously with doses separated by ≥7 days, or 1,600 mg rituximab + 26,800 units hyaluronidase as specified for the indication (policy details per condition).

Policy lists both indications with supportive evidence and specified dosing permutations.

Hodgkin lymphoma, Kaposi sarcoma, Waldenstrom's specific notes: Approve for 1 year if ALL general requirements are met. Hodgkin (nodular lymphocyte‑predominant): general dosing options per policy. Kaposi sarcoma (KICS): dosing may be 1,600 mg or 1,400 mg with doses separated by ≥7 days. Waldenstrom's: dosing may be 1,600 mg or 1,400 mg with a maximum of four doses per 28‑day cycle.

See policy dosing table for exact regimen per disease.

Coverage of Rituxan Hycela is not recommended for certain indications where the subcutaneous formulation has not been evaluated and dosing is not established. Specifically, do not approve Rituxan Hycela for treatment of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, because intravenous rituximab is the indicated formulation and Rituxan Hycela lacks an established dosing regimen in these conditions. Likewise, Rituxan Hycela is not recommended for pemphigus vulgaris or rheumatoid arthritis for the same reasons. Requests for uses not listed in the Recommended Authorization Criteria should also be denied until updated evidence and dosing guidance are available.

Regimens and Dosing

Regimen / Indication	Rituxan Hycela dosing (fixed SC)	Notes / Requirements	Coverage status
Diffuse large B-cell lymphoma (in combination with CHOP or other anthracycline-based chemotherapy)
1,400 mg rituximab + 23,400 units hyaluronidase OR 1,600 mg rituximab + 26,800 units hyaluronidase (fixed SC)
Approve when patient has received at least one full IV rituximab induction dose; administer under care of healthcare professional; reduce chemo doses as needed for toxicity.
Covered with criteria

Billing and Codes

Applicable billing codesmixed

not specified

Policy references medical benefit prior authorization; specific HCPCS/CPT/NDC codes not listed in document.

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Recommended

Prior Authorization Recommended — Prior authorization is recommended for medical benefit coverage of Rituxan Hycela. Approvals are provided for the durations noted in the policy (commonly 1 year). Because of the specialized skills required for evaluation, diagnosis, and monitoring, Rituxan Hycela must be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for the duration noted; when authorized in months, 1 month = 30 days.

Approvals are typically for 1 year where indicated
Prescriptions should be by or in consultation with an oncologist or specialist
Requests for doses outside established dosing will be reviewed case-by-case by a clinician (e.g., Medical Director or Pharmacist)

Documentation Required

IV Induction Required Before SC Administration

IV induction required before subcutaneous Rituxan Hycela — All patients must receive at least one full intravenous (IV) dose of a rituximab product before initiating Rituxan Hycela subcutaneously. Patients who are unable to complete a full IV infusion should continue with IV rituximab for subsequent cycles and must not be switched to Rituxan Hycela until a full IV dose has been successfully administered.

Therapy Line (First-line and Later)

first-line and later

Line of therapy notes: Rituxan Hycela may be used in first‑line and relapsed/refractory (later‑line) settings in clinical scenarios where intravenous rituximab is recommended by NCCN, provided the patient has received the first full IV rituximab dose.

Use with indicated chemotherapy regimens as listed in NCCN when the IV induction requirement is met.

Definitions and Background

inv-09: Rituxan Hycela — definition and fixed-dose description

DefinitionRituxan Hycela: a fixed‑dose subcutaneous combination of rituximab (a CD20‑directed cytolytic antibody) plus hyaluronidase human to facilitate systemic delivery.

Fixed‑dose descriptionDose is fixed regardless of patient body surface area; dose reductions are not recommended.

Administration setting requirementShould be administered under the care of a healthcare professional with appropriate medical support to manage severe and potentially fatal reactions.

IV induction requirementTreatment should only be initiated after the patient has received at least one full dose of a rituximab product by intravenous infusion.

Indication scopeIndicated for treatment of adults for multiple B‑cell malignancies (examples include DLBCL with CHOP, CLL in combination with FC, and follicular lymphoma as described in product labeling).

Policy Summary

Payerculinary health fund

PolicyRituxan Hycela (rituximab + hyaluronidase) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 18, 2026

Key ActionObtain prior authorization and document at least one full IV rituximab dose before initiating Rituxan Hycela.

SourceLink

On This Page

Requirement applies to all FDA-approved indications in this policy (e.g., B‑cell lymphoma, CLL/SLL)
Safety rationale: higher risk of hypersensitivity and acute reactions during first infusion — IV allows slowing/stopping to manage reactions

Documentation Required

Prescriber and Administration Documentation

Prescriber and administration documentation — Rituxan Hycela must be administered under the care of a healthcare professional and prescribed by or in consultation with an oncologist (or specialist in the treated condition). Documentation of the prior IV rituximab infusion (date, dose, and that a full infusion was completed) and the treating prescriber’s specialty should be included with authorization requests.

Include documentation that at least one full IV rituximab dose was completed (date and dose)
Confirm administration will occur under healthcare professional supervision
Note prescriber is an oncologist or consult with appropriate specialist

Denial Risk

Unsupported Indication Denial Risk

Unsupported indication denial risk — Requests for indications not listed in the Recommended Authorization Criteria or those listed in 'Conditions Not Recommended for Approval' (for example: granulomatosis with polyangiitis, microscopic polyangiitis, pemphigus vulgaris, rheumatoid arthritis) carry a risk of denial because Rituxan Hycela has not been evaluated or does not have established dosing for these conditions.

Do not request Rituxan Hycela for indications where IV rituximab is the indicated formulation and Hycela lacks established dosing
Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria

Rituxan Hycela is a fixed‑dose subcutaneous combination of the anti‑CD20 monoclonal antibody rituximab and hyaluronidase human that enables systemic delivery via the subcutaneous route. The formulation provides the same rituximab antibody as intravenous Rituxan but mixed with hyaluronidase to allow a single, fixed‑volume subcutaneous injection rather than weight‑based IV dosing.

Because hypersensitivity and other acute infusion reactions are more likely during the first exposure to rituximab, the policy requires that patients receive at least one full intravenous dose of a rituximab product before initiating Rituxan Hycela subcutaneously; this IV induction mitigates the risk associated with initial rituximab administration.

Prior authorization is recommended for medical benefit coverage, and approvals are commonly issued for 1 year. The policy and guidelines (NCCN and prescribing information) support use of Rituxan Hycela for multiple B‑cell malignancies and select hematologic disorders when the IV induction and other stated criteria are met.